Loxo Oncology Company Profile (NASDAQ:LOXO)

About Loxo Oncology (NASDAQ:LOXO)

Loxo Oncology logoLoxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:LOXO
  • CUSIP: N/A
  • Web: www.loxooncology.com
Capitalization:
  • Market Cap: $1.94008 billion
  • Outstanding Shares: 29,853,000
Average Prices:
  • 50 Day Moving Avg: $74.35
  • 200 Day Moving Avg: $55.81
  • 52 Week Range: $17.14 - $83.12
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.70
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $15.46 per share
  • Price / Book: 4.62
Profitability:
  • EBIDTA: ($101,070,000.00)
  • Return on Equity: -40.53%
  • Return on Assets: -38.82%
Debt:
  • Current Ratio: 42.17%
  • Quick Ratio: 42.17%
Misc:
  • Average Volume: 475,442 shs.
  • Beta: 2.81
  • Short Ratio: 3.94
 

Frequently Asked Questions for Loxo Oncology (NASDAQ:LOXO)

What is Loxo Oncology's stock symbol?

Loxo Oncology trades on the NASDAQ under the ticker symbol "LOXO."

How were Loxo Oncology's earnings last quarter?

Loxo Oncology, Inc. (NASDAQ:LOXO) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.99) by $0.15. During the same quarter last year, the company earned ($0.77) EPS. View Loxo Oncology's Earnings History.

Where is Loxo Oncology's stock going? Where will Loxo Oncology's stock price be in 2017?

7 brokers have issued 1 year target prices for Loxo Oncology's stock. Their predictions range from $50.00 to $94.00. On average, they anticipate Loxo Oncology's share price to reach $79.20 in the next twelve months. View Analyst Ratings for Loxo Oncology.

What are analysts saying about Loxo Oncology stock?

Here are some recent quotes from research analysts about Loxo Oncology stock:

  • 1. According to Zacks Investment Research, "Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut. " (8/12/2017)
  • 2. BTIG Research analysts commented, "Today LOXO announced the acquisition of REDX08608 (LOXO-305) from Redx Pharma (REDX, Not Rated), a reversible BTK inhibitor that is effective against both wild-type and mutant C481S BTK. We view the acquisition of REDX08608 positively, as the ~$40m upfront acquisition cost is relatively devoid of downstream payments (milestones etc.), and despite the BTK space being competitive with next generation programs to ibrutinib, we think there will be ample room for multiple BTK inhibitors and we also favor the selectivity of LOXO-305. Management has guided for the submission of an IND during 2018. We reiterate our Buy rating and $75 PT." (8/3/2017)

Who are some of Loxo Oncology's key competitors?

Who are Loxo Oncology's key executives?

Loxo Oncology's management team includes the folowing people:

  • Joshua H. Bilenker M.D., President, Chief Executive Officer, Director
  • Jennifer Burstein CPA, Vice President - Finance
  • Jacob S. Van Naarden, Chief Business Officer
  • Keith T. Flaherty M.D., Director
  • Lori A. Kunkel M.D., Director
  • David Bonita M.D., Independent Director
  • Steven A. Elms, Independent Director
  • Alan Fuhrman, Independent Director

Who owns Loxo Oncology stock?

Loxo Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (16.81%), BlackRock Inc. (6.13%), Alliancebernstein L.P. (3.58%), Vanguard Group Inc. (3.50%), Victory Capital Management Inc. (3.06%) and State Street Corp (1.81%). Company insiders that own Loxo Oncology stock include Aisling Capital Iii Lp, Avi Z Naider, David P Bonita, Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty and Naarden Jacob Van. View Institutional Ownership Trends for Loxo Oncology.

Who sold Loxo Oncology stock? Who is selling Loxo Oncology stock?

Loxo Oncology's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Franklin Resources Inc., AXA, PointState Capital LP, EAM Investors LLC, Candriam Luxembourg S.C.A., Strs Ohio and Russell Investments Group Ltd.. Company insiders that have sold Loxo Oncology stock in the last year include Jennifer Burstein, Joshua H Bilenker, Keith T Flaherty and Naarden Jacob Van. View Insider Buying and Selling for Loxo Oncology.

Who bought Loxo Oncology stock? Who is buying Loxo Oncology stock?

Loxo Oncology's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Alliancebernstein L.P., BlackRock Inc., Voya Investment Management LLC, Pictet Asset Management Ltd., Vanguard Group Inc. and Sectoral Asset Management Inc. Company insiders that have bought Loxo Oncology stock in the last two years include Aisling Capital Iii Lp and Avi Z Naider. View Insider Buying and Selling for Loxo Oncology.

How do I buy Loxo Oncology stock?

Shares of Loxo Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Loxo Oncology's stock price today?

One share of Loxo Oncology stock can currently be purchased for approximately $71.50.


MarketBeat Community Rating for Loxo Oncology (NASDAQ LOXO)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Loxo Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Loxo Oncology (NASDAQ:LOXO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $79.20 (10.77% upside)

Analysts' Ratings History for Loxo Oncology (NASDAQ:LOXO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/8/2017Ifs SecuritiesReiterated RatingOutperformLowView Rating Details
8/10/2017Stifel NicolausReiterated RatingBuy$71.00 -> $94.00HighView Rating Details
8/3/2017BTIG ResearchReiterated RatingBuy$75.00LowView Rating Details
6/19/2017Morgan StanleyReiterated RatingOverweight$91.00HighView Rating Details
6/5/2017Cowen and CompanyReiterated RatingOutperformLowView Rating Details
6/5/2017Citigroup Inc.UpgradeNeutral -> Buy$86.00HighView Rating Details
2/8/2017Jefferies Group LLCInitiated CoverageBuy$50.00N/AView Rating Details
4/19/2016Oppenheimer Holdings, Inc.Reiterated RatingOutperform$30.00N/AView Rating Details
11/11/2015JMP SecuritiesBoost Price Target$26.00 -> $29.00N/AView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for Loxo Oncology (NASDAQ:LOXO)
Earnings by Quarter for Loxo Oncology (NASDAQ:LOXO)
Earnings History by Quarter for Loxo Oncology (NASDAQ LOXO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.99)($1.14)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.76)($0.96)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.85)($1.28)ViewN/AView Earnings Details
11/2/2016Q316($0.74)($0.82)ViewN/AView Earnings Details
8/3/2016Q2($0.63)($0.77)ViewN/AView Earnings Details
5/4/2016Q1($0.69)($0.59)ViewN/AView Earnings Details
3/15/2016Q4($0.53)($0.73)ViewN/AView Earnings Details
11/10/2015Q3($0.53)($0.53)ViewN/AView Earnings Details
8/5/2015Q215($0.45)($0.49)ViewListenView Earnings Details
5/14/2015Q1($0.50)($0.38)ViewN/AView Earnings Details
11/14/2014Q314($0.37)($0.68)ViewN/AView Earnings Details
9/12/2014Q2 2014($12.27)($14.46)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Loxo Oncology (NASDAQ:LOXO)
2017 EPS Consensus Estimate: ($3.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.75)($0.75)($0.75)
Q2 20171($0.83)($0.83)($0.83)
Q3 20171($0.92)($0.92)($0.92)
Q4 20171($1.18)($1.18)($1.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Loxo Oncology (NASDAQ:LOXO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Loxo Oncology (NASDAQ:LOXO)
Insider Ownership Percentage: 44.40%
Insider Trades by Quarter for Loxo Oncology (NASDAQ:LOXO)
Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)
Insider Trades by Quarter for Loxo Oncology (NASDAQ:LOXO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2017Joshua H BilenkerCEOSell15,000$73.56$1,103,400.00View SEC Filing  
8/15/2017Naarden Jacob VanInsiderSell3,082$73.57$226,742.74View SEC Filing  
8/14/2017Jennifer BursteinVPSell1,700$73.73$125,341.00View SEC Filing  
8/14/2017Joshua H BilenkerCEOSell7,500$73.73$552,975.00View SEC Filing  
8/14/2017Naarden Jacob VanInsiderSell1,541$73.73$113,617.93View SEC Filing  
5/22/2017Keith T FlahertyDirectorSell7,250$45.09$326,902.50View SEC Filing  
1/10/2017Aisling Capital Iii LpMajor ShareholderBuy160,000$31.00$4,960,000.00View SEC Filing  
12/19/2016Keith T FlahertyDirectorSell7,250$30.23$219,167.50View SEC Filing  
9/7/2016Keith T FlahertyDirectorSell14,500$30.00$435,000.00View SEC Filing  
8/11/2016Keith T FlahertyDirectorSell15,000$26.00$390,000.00View SEC Filing  
8/10/2016David P BonitaDirectorSell447,857$26.96$12,074,224.72View SEC Filing  
5/17/2016Aisling Capital Iii LpMajor ShareholderBuy232,558$21.50$4,999,997.00View SEC Filing  
11/17/2015Avi Z NaiderDirectorBuy3,773$26.50$99,984.50View SEC Filing  
11/13/2015Aisling Capital Iii LpMajor ShareholderBuy78,669$27.65$2,175,197.85View SEC Filing  
8/6/2014James E FlynnInsiderBuy1,089,656$13.01$14,176,424.56View SEC Filing  
8/6/2014Orbimed Advisors LlcMajor ShareholderBuy275,385$13.00$3,580,005.00View SEC Filing  
8/6/2014Steve ElmsDirectorBuy413,077$13.00$5,370,001.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Loxo Oncology (NASDAQ:LOXO)
Latest Headlines for Loxo Oncology (NASDAQ:LOXO)
Source:
DateHeadline
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Insider Naarden Jacob Van Sells 1,541 Shares
www.americanbankingnews.com - August 16 at 8:48 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) VP Sells $125,341.00 in Stock
www.americanbankingnews.com - August 16 at 8:46 PM
americanbankingnews.com logoInsider Selling: Loxo Oncology, Inc. (LOXO) Insider Sells 3,082 Shares of Stock
www.americanbankingnews.com - August 16 at 8:46 PM
americanbankingnews.com logoInsider Selling: Loxo Oncology, Inc. (LOXO) CEO Sells 7,500 Shares of Stock
www.americanbankingnews.com - August 16 at 8:28 PM
americanbankingnews.com logoJoshua H. Bilenker Sells 15,000 Shares of Loxo Oncology, Inc. (LOXO) Stock
www.americanbankingnews.com - August 16 at 7:58 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 12 at 8:56 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 12 at 2:50 PM
americanbankingnews.com logoBidaskClub Upgrades Loxo Oncology, Inc. (NASDAQ:LOXO) to Hold
www.americanbankingnews.com - August 12 at 11:20 AM
americanbankingnews.com logoIfs Securities Reaffirms "Outperform" Rating for Loxo Oncology, Inc. (LOXO)
www.americanbankingnews.com - August 11 at 4:00 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Loxo Oncology Inc.
finance.yahoo.com - August 11 at 6:11 AM
americanbankingnews.com logo Analysts Anticipate Loxo Oncology, Inc. (LOXO) Will Post Earnings of -$0.99 Per Share
www.americanbankingnews.com - August 9 at 7:46 AM
finance.yahoo.com logoLoxo Oncology Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 10:24 PM
finance.yahoo.com logoLoxo reports 2Q loss
finance.yahoo.com - August 8 at 10:24 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Posts Earnings Results, Misses Estimates By $0.16 EPS
www.americanbankingnews.com - August 8 at 9:59 AM
americanbankingnews.com logoLoxo Oncology, Inc. (NASDAQ:LOXO) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - August 4 at 10:36 PM
finance.yahoo.com logoLoxo Oncology Announces Acquisition of Highly Selective, Reversible BTK Inhibitor Program
finance.yahoo.com - July 31 at 7:55 PM
prnewswire.com logoAmgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation
www.prnewswire.com - July 18 at 5:00 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 18 at 3:10 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Downgraded by BidaskClub
www.americanbankingnews.com - July 17 at 12:00 AM
americanbankingnews.com logoZacks: Analysts Expect Loxo Oncology, Inc. (LOXO) to Announce -$1.01 Earnings Per Share
www.americanbankingnews.com - June 23 at 10:22 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 23 at 12:34 PM
finance.yahoo.com logoFDA to Clear Path for Drugs Aimed at Cancer-Causing Genes
finance.yahoo.com - June 20 at 7:18 PM
finance.yahoo.com logoTrump drug pricing order may be weeks away
finance.yahoo.com - June 20 at 7:18 PM
americanbankingnews.com logoLoxo Oncology, Inc. (LOXO) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - June 19 at 5:38 PM
finance.yahoo.com logoCancer's Big Infrastructure Problem
finance.yahoo.com - June 16 at 7:27 AM
finance.yahoo.com logo[$$] Loxo Strikes While the Biotech Iron is Hot
finance.yahoo.com - June 16 at 7:27 AM
streetinsider.com logoLoxo Oncology (LOXO) Announces Common Offering
www.streetinsider.com - June 13 at 11:31 PM
rttnews.com logoLoxo Oncology Inc. (LOXO) Is Losing Ground On Offering News
www.rttnews.com - June 13 at 6:31 PM
reuters.com logoBRIEF-Loxo Oncology announces proposed public offering of common stock
www.reuters.com - June 13 at 6:31 PM
finance.yahoo.com logoLoxo Oncology Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 13 at 6:31 PM
finance.yahoo.com logoLoxo Oncology launching secondary offering to fund drug research
finance.yahoo.com - June 13 at 6:31 PM
finance.yahoo.com logoPrecision Oncology Drug Yields Impressive Results, Showing Power Of Cancer Genomics
finance.yahoo.com - June 9 at 9:04 AM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - June 8 at 9:44 PM
nasdaq.com logoLOXO Crosses Above Average Analyst Target
www.nasdaq.com - June 6 at 7:01 PM
rttnews.com logoLoxo Oncology Inc. (LOXO) Soared To A New High On Study Results
www.rttnews.com - June 6 at 9:44 AM
americanbankingnews.com logoBTIG Research Reiterates "Buy" Rating for Loxo Oncology Inc (LOXO)
www.americanbankingnews.com - June 6 at 7:58 AM
finance.yahoo.com logoASCO: Loxo Oncology shares up on cancer drug announcement...
finance.yahoo.com - June 6 at 12:05 AM
finance.yahoo.com logoLoxo stock soars on drug trial results: CEO
finance.yahoo.com - June 6 at 12:05 AM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Given Outperform Rating at Cowen and Company
www.americanbankingnews.com - June 5 at 10:00 PM
nasdaq.com logoLoxo Oncology Inc. (LOXO) Has Leaped To A New High After Publication
www.nasdaq.com - June 5 at 7:03 PM
finance.yahoo.com logoHere Are Winners And Losers From Year's Biggest Cancer Meeting
finance.yahoo.com - June 5 at 7:03 PM
feeds.benzinga.com logo12 Biggest Mid-Day Gainers For Monday
feeds.benzinga.com - June 5 at 12:58 PM
investorplace.com logoLoxo Oncology Inc (LOXO) Shares Skyrocket on Successful Cancer Drug Trial
investorplace.com - June 5 at 12:20 PM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) Raised to "Buy" at Citigroup Inc
www.americanbankingnews.com - June 5 at 11:04 AM
finance.yahoo.com logoLoxo Oncology jumps 34% premarket on news of positive cancer drug trial
finance.yahoo.com - June 5 at 9:39 AM
finance.yahoo.com logoBiotech Movers: Loxo, NewLink, BioCryst
finance.yahoo.com - June 5 at 9:39 AM
americanbankingnews.com logoLoxo Oncology Inc (LOXO) PT Raised to $71.00
www.americanbankingnews.com - June 5 at 9:15 AM
wsj.com logoExperimental Drug Targets Same Genetic Defect Shared by Different Cancers
www.wsj.com - June 4 at 11:30 PM
finance.yahoo.com logoCancer Drug Targeting Rare Mutation Works Across Tumor Types
finance.yahoo.com - June 3 at 5:56 PM
finance.yahoo.com logoA New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
finance.yahoo.com - June 3 at 5:56 PM

Social

Chart

Loxo Oncology (LOXO) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff